Knowledge Synthesis and Application Unit, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Knowledge Synthesis Group, Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Syst Rev. 2024 Jan 31;13(1):48. doi: 10.1186/s13643-023-02447-3.
The transition from childhood to adolescence is associated with an increase in rates of some psychiatric disorders, including major depressive disorder, a debilitating mood disorder. The aim of this systematic review is to update the evidence on the benefits and harms of screening for depression in primary care and non-mental health clinic settings among children and adolescents.
This review is an update of a previous systematic review, for which the last search was conducted in 2017. We searched Ovid MEDLINE® ALL, Embase Classic+Embase, PsycINFO, Cochrane Central Register of Controlled Trials, and CINAHL on November 4, 2019, and updated on February 19, 2021. If no randomized controlled trials were found, we planned to conduct an additional search for non-randomized trials with a comparator group. For non-randomized trials, we applied a non-randomized controlled trial filter and searched the same databases except for Cochrane Central Register of Controlled Trials from January 2015 to February 2021. We also conducted a targeted search of the gray literature for unpublished documents. Title and abstract, and full-text screening were completed independently by pairs of reviewers.
In this review update, we were unable to find any randomized controlled studies that satisfied our eligibility criteria and evaluated the potential benefits and harms of screening for depression in children and adolescents. Additionally, a search for non-randomized trials yielded no studies that met the inclusion criteria.
The findings of this review indicate a lack of available evidence regarding the potential benefits and harms of screening for depression in children and adolescents. This absence of evidence emphasizes the necessity for well-conducted clinical trials to evaluate the effectiveness of depression screening among children and adolescents in primary care and non-mental health clinic settings.
PROSPERO CRD42020150373 .
从儿童期到青春期的过渡与某些精神疾病(包括重度抑郁症,一种使人虚弱的情绪障碍)发生率的增加有关。本系统评价的目的是更新初级保健和非心理健康诊所环境中儿童和青少年抑郁筛查的益处和危害的证据。
这是对先前系统评价的更新,最后一次搜索是在 2017 年进行的。我们于 2019 年 11 月 4 日在 Ovid MEDLINE® ALL、Embase Classic+Embase、PsycINFO、Cochrane 对照试验中心注册库和 CINAHL 上进行了检索,并于 2021 年 2 月 19 日进行了更新。如果未发现随机对照试验,我们计划针对具有对照组的非随机试验进行额外搜索。对于非随机试验,我们应用非随机对照试验过滤器,并从 2015 年 1 月至 2021 年 2 月对除 Cochrane 对照试验中心注册库以外的相同数据库进行搜索。我们还针对未发表的文件对灰色文献进行了有针对性的搜索。标题和摘要以及全文筛选均由 pairs of reviewers 独立完成。
在本次审查更新中,我们未能找到任何符合我们的纳入标准并评估儿童和青少年抑郁筛查潜在益处和危害的随机对照研究。此外,对非随机试验的搜索也没有找到符合纳入标准的研究。
本综述的结果表明,缺乏关于儿童和青少年抑郁筛查潜在益处和危害的可用证据。这种缺乏证据强调了需要进行精心设计的临床试验,以评估初级保健和非心理健康诊所环境中儿童和青少年抑郁筛查的有效性。
PROSPERO CRD42020150373。